昨年、OraSure Technologies Incは最も業績の良かった部門であるNet product and services revenues - HIVで49.80M USDの売上を計上しました。地域別ではUnited Statesが最も大きく貢献し、昨年の売上高は78.25M USDに達しました。直近の四半期において、OraSure Technologies Incは2026-06-30に終了した期間の売上高として14.17M USDを報告しました。これは最も好調な部門であるNet product and services revenues - COVID-19によるものです。地域別ではUnited Statesが最も高く、20.23M USDを貢献しました。

事業別

収益

比率

年間

年間

四半期

Net product and services revenues - HIV

Net product and services revenues - Microbiome

Net product and services revenues - HCV

Other revenues - Other non Product revenues

Net product and services revenues - Other Products revenue

Other revenues

Net product and services revenues - Risk assessment testing

Net product and services revenues - COVID-19

Net product and service revenues -Molecular Services

Net product and service revenues -Molecular Products

Net product and services revenues - Genomics

Net product and services revenues - Laboratory services

Other revenues - Royalty Income

Net product and services revenues - Infectious disease testing

Net product and services revenues - OraQuick

Net product and services revenues - Oragene

Net product and services revenues - ORAcollect

Net product and services revenues - Intercept

Net product and services revenues - Microbiome laboratory services

Net product and services revenues - Histofreezer

Net product and services revenues - OMNIgene® • GUT

Research and development funding

Grant funding

Charitable Support reimbursement

BARDA Funding

AbbVie Exclusivity

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

Net product and services revenues - HIV

49.80M(41.62%)

60.80M(32.11%)

60.82M(14.92%)

38.81M(9.94%)

--(--)

Net product and services revenues - Microbiome

38.36M(32.05%)

--(--)

7.50M(1.92%)

7.94M(3.36%)

6.16M(3.58%)

--(--)

Net product and services revenues - HCV

13.76M(11.50%)

14.02M(7.41%)

12.87M(3.16%)

13.37M(3.42%)

--(--)

Other revenues - Other non Product revenues

5.97M(4.99%)

1.22M(0.64%)

3.25M(0.80%)

6.75M(1.73%)

2.36M(1.00%)

1.91M(1.11%)

--(--)

Net product and services revenues - Other Products revenue

4.65M(3.88%)

3.51M(1.85%)

2.27M(0.56%)

3.14M(0.80%)

2.57M(1.09%)

117.00K(0.07%)

9.52M(5.80%)

19.04M(9.48%)

Other revenues

4.65M(3.88%)

3.51M(1.85%)

2.27M(0.56%)

3.14M(0.80%)

2.57M(1.09%)

117.00K(0.07%)

9.52M(5.80%)

19.04M(9.48%)

Net product and services revenues - Risk assessment testing

1.87M(1.56%)

8.35M(4.41%)

9.74M(2.39%)

10.27M(2.63%)

9.68M(4.10%)

9.37M(5.46%)

--(--)

Net product and services revenues - COVID-19

624.00K(0.52%)

45.17M(23.86%)

257.78M(63.22%)

243.32M(62.29%)

76.87M(32.54%)

49.80M(28.98%)

--(--)

Net product and service revenues -Molecular Services

--(--)

1.71M(0.90%)

4.47M(1.10%)

--(--)

Net product and service revenues -Molecular Products

--(--)

51.05M(26.96%)

54.27M(13.31%)

--(--)

Net product and services revenues - Genomics

--(--)

54.34M(13.91%)

63.35M(26.82%)

37.14M(21.61%)

--(--)

Net product and services revenues - Laboratory services

--(--)

7.30M(1.87%)

11.84M(5.01%)

9.56M(5.57%)

--(--)

Other revenues - Royalty Income

--(--)

2.68M(0.69%)

4.42M(1.87%)

3.43M(2.00%)

5.12M(3.12%)

9.65M(4.81%)

Net product and services revenues - Infectious disease testing

--(--)

54.65M(23.13%)

54.23M(31.56%)

--(--)

Net product and services revenues - OraQuick

--(--)

56.06M(34.16%)

53.85M(26.82%)

Net product and services revenues - Oragene

--(--)

46.70M(28.45%)

75.85M(37.78%)

Net product and services revenues - ORAcollect

--(--)

10.65M(6.49%)

--(--)

Net product and services revenues - Intercept

--(--)

8.11M(4.94%)

7.71M(3.84%)

Net product and services revenues - Microbiome laboratory services

--(--)

6.10M(3.72%)

--(--)

Net product and services revenues - Histofreezer

--(--)

5.70M(3.47%)

8.98M(4.47%)

Net product and services revenues - OMNIgene® • GUT

--(--)

5.23M(3.18%)

--(--)

Research and development funding

--(--)

851.00K(0.52%)

--(--)

Grant funding

--(--)

304.00K(0.19%)

--(--)

Charitable Support reimbursement

--(--)

261.00K(0.16%)

1.71M(0.85%)

BARDA Funding

--(--)

4.95M(2.47%)

AbbVie Exclusivity

--(--)

地域別

収益

比率

年間

年間

四半期

United States

Africa (Region)

Europe

Other Regions

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

FY2014

FY2013

FY2012

FY2011

United States

78.25M(68.03%)

139.16M(74.89%)

361.66M(89.19%)

350.21M(90.38%)

188.38M(80.62%)

130.84M(76.19%)

107.28M(69.39%)

136.85M(75.30%)

121.46M(72.70%)

99.76M(77.82%)

96.52M(80.62%)

82.26M(77.26%)

77.19M(78.02%)

67.46M(76.82%)

67.64M(82.61%)

Africa (Region)

23.99M(20.86%)

32.74M(17.62%)

--(--)

Europe

7.39M(6.43%)

8.42M(4.53%)

8.11M(2.00%)

11.54M(2.98%)

13.80M(5.91%)

12.07M(7.03%)

11.75M(7.60%)

11.06M(6.09%)

11.83M(7.08%)

11.65M(9.08%)

13.54M(11.31%)

13.91M(13.07%)

11.08M(11.20%)

10.13M(11.54%)

7.51M(9.17%)

Other Regions

5.38M(4.68%)

5.50M(2.96%)

35.70M(8.80%)

25.74M(6.64%)

31.49M(13.48%)

28.82M(16.78%)

35.57M(23.01%)

33.83M(18.62%)

33.78M(20.22%)

16.79M(13.10%)

9.66M(8.07%)

10.29M(9.67%)

10.66M(10.78%)

10.23M(11.65%)

6.73M(8.22%)